TP53 and non-small cell lung carcinoma: In the present study, we examined the role of p53 as predictive biomarker for volasertib treatment in a panel of NSCLC cell lines differing in p53 status, including an isogenic knockdown cell line, under both normal and reduced oxygen conditions.